Keay Nakae
Stock Analyst at Chardan Capital
(4.31)
# 363
Out of 5,127 analysts
255
Total ratings
40.64%
Success rate
24.79%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $58.27 | +71.61% | 7 | Jan 29, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $7 → $15 | $12.74 | +17.74% | 5 | Jan 29, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.90 | +185.71% | 23 | Jan 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 → $80 | $62.64 | +27.71% | 23 | Jan 7, 2026 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $2 | $0.29 | +599.30% | 1 | Jan 5, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $35 | $31.97 | +9.49% | 1 | Jan 5, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $30 | $16.84 | +78.15% | 1 | Jan 5, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $4.23 | +183.69% | 19 | Dec 18, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $16.99 | +123.66% | 14 | Dec 9, 2025 | |
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $1.08 | +131.48% | 7 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.05 | +23.46% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $3.93 | +409.55% | 13 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 | $72.89 | -1.22% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.47 | +172.11% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $4.51 | +676.05% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $320.00 | +25.00% | 14 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $2.41 | +107.47% | 5 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $14.55 | -58.76% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.79 | +235.20% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.53 | +1,406.02% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $16.78 | -64.24% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $4.53 | +8,288.52% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $11.03 | +398.64% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.35 | +129.89% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $29.81 | +193.53% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.38 | +842.03% | 3 | Feb 9, 2021 |
Monopar Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $100
Current: $58.27
Upside: +71.61%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $12.74
Upside: +17.74%
Coya Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $14
Current: $4.90
Upside: +185.71%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $62.64
Upside: +27.71%
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $2
Current: $0.29
Upside: +599.30%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $31.97
Upside: +9.49%
Alto Neuroscience
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $16.84
Upside: +78.15%
SAB Biotherapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $4.23
Upside: +183.69%
Dyne Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $38
Current: $16.99
Upside: +123.66%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.08
Upside: +131.48%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.05
Upside: +23.46%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $3.93
Upside: +409.55%
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $72.89
Upside: -1.22%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.47
Upside: +172.11%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $4.51
Upside: +676.05%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $320.00
Upside: +25.00%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $2.41
Upside: +107.47%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $14.55
Upside: -58.76%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.79
Upside: +235.20%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.53
Upside: +1,406.02%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $16.78
Upside: -64.24%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $4.53
Upside: +8,288.52%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $11.03
Upside: +398.64%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.35
Upside: +129.89%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $29.81
Upside: +193.53%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.38
Upside: +842.03%